Linker et al., 2008 - Google Patents
Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studiesLinker et al., 2008
- Document ID
- 3294976105549606538
- Author
- Linker R
- Lee D
- Stangel M
- Gold R
- Publication year
- Publication venue
- Expert Review of Neurotherapeutics
External Links
Snippet
All licensed disease-modifying drugs for the treatment of relapsing–remitting multiple sclerosis (MS) only display partial efficacy and hitherto require parenteral administration. Thus, there is a high demand for innovative and at the same time orally available MS …
- 201000006417 multiple sclerosis 0 title abstract description 48
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Linker et al. | Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy | |
| Fox et al. | BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety | |
| Mrowietz et al. | The pharmacokinetics of fumaric acid esters reveal their in vivo effects | |
| Engelen et al. | International recommendations for the diagnosis and management of patients with adrenoleukodystrophy: a consensus-based approach | |
| Gold et al. | Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis | |
| Kappos et al. | Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study | |
| Kappos et al. | Effect of BG-12 on contrast-enhanced lesions in patients with relapsing–remitting multiple sclerosis: subgroup analyses from the phase 2b study | |
| Fazekas et al. | Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial | |
| Brück et al. | Therapeutic decisions in multiple sclerosis: moving beyond efficacy | |
| Birnbaum et al. | Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis | |
| Riccio et al. | Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study | |
| Mrowietz et al. | Dimethylfumarate for psoriasis: more than a dietary curiosity | |
| Papp et al. | Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial | |
| Michell‐Robinson et al. | Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis | |
| Gold et al. | Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action | |
| Kimball et al. | Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial | |
| Linker et al. | Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies | |
| Phillips et al. | BG-12 in multiple sclerosis | |
| Papp et al. | Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1) | |
| Deeks | Dimethyl fumarate: a review in relapsing-remitting MS | |
| Rauma et al. | Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study | |
| Georges et al. | Impact of pain in health related quality of life of patients with systemic sclerosis | |
| Nasser et al. | A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects | |
| Papadopoulou et al. | Teriflunomide for oral therapy in multiple sclerosis | |
| Ruggiero et al. | Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge |